Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
SAN DIEGO, Feb. 24, 2016 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, will release its fourth quarter and full year 2015 financial results after the market closes on Tuesday, March 8, 2016. The press release will be followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss other business matters.
The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 44479307. Participants may access the live webcast via a link on the Vital Therapies website in the Investors Relations section under Events at: http://ir.vitaltherapies.com/. The webcast will be archived on the Company's website shortly after completion of the call.
For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call beginning approximately 7:30 p.m. ET on March 8, 2016. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 44479307.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact: Vital Therapies, Inc. Al Kildani Vice President, Investor Relations and Business Development 858-673-6840 [email protected]
